HC Wainwright Issues Positive Outlook for ChromaDex Earnings

ChromaDex Co. (NASDAQ:CDXC - Free Report) - Equities researchers at HC Wainwright increased their FY2025 earnings per share estimates for shares of ChromaDex in a note issued to investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.21 per share for the year, up from their previous forecast of $0.12. HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for ChromaDex's current full-year earnings is $0.01 per share.

ChromaDex (NASDAQ:CDXC - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The firm had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same period in the previous year, the business earned ($0.01) EPS.

Separately, Roth Mkm lifted their price target on ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday.

ChromaDex Price Performance

CDXC traded up $0.88 on Wednesday, reaching $6.99. 1,908,432 shares of the stock were exchanged, compared to its average volume of 506,507. The company's 50-day moving average price is $3.70 and its 200 day moving average price is $3.28. ChromaDex has a fifty-two week low of $1.32 and a fifty-two week high of $7.08. The firm has a market capitalization of $530.77 million, a PE ratio of 699.00 and a beta of 1.88.

Insiders Place Their Bets

In other news, Director Kristin Patrick sold 23,000 shares of the business's stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ChromaDex

Several institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC increased its stake in shares of ChromaDex by 8.4% in the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company's stock valued at $1,136,000 after purchasing an additional 32,400 shares in the last quarter. WINTON GROUP Ltd purchased a new position in shares of ChromaDex in the 2nd quarter valued at about $597,000. Bank of New York Mellon Corp increased its stake in shares of ChromaDex by 170.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company's stock valued at $520,000 after purchasing an additional 119,915 shares in the last quarter. BSW Wealth Partners purchased a new stake in ChromaDex during the 3rd quarter worth approximately $324,000. Finally, OneDigital Investment Advisors LLC increased its stake in ChromaDex by 5.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company's stock worth $217,000 after buying an additional 3,097 shares in the last quarter. Hedge funds and other institutional investors own 15.41% of the company's stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.